Privi Speciality Chemicals Limited (PRIVISCL)
₹3,349.00 -0.48% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Privi Speciality's revenue was ₹666 Cr (+19.2% year on year, -7.8% on the previous quarter), and net profit ₹83.0 Cr (+44.2% year on year); the operating margin was 22.8%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹666 | +19.2% | -7.8% |
| Operating profit | ₹152 | +15.1% | -15.6% |
| Net profit | ₹83.0 | +44.2% | -11.7% |
| EPS (₹) | 21.54 | +35.9% | -10.1% |
| Operating margin | 22.8% | — | — |
PRIVISCL delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 68.81% of the PRIVISCL shares traded on NSE were taken to delivery, against the stock's own 20-session average of 56.64%. Delivery was unusually high while the price barely moved (-0.48%). Volume was 0.3 times its average, well below normal.
Delivery in the last 5 sessions: 62.8% · 50.0% · 40.7% · 57.0% · 68.8%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Privi Speciality Chemicals Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the second quarter ended September 30, 2026. Registrar and Share Transfer Agent MUFG Intime India confirmed that all securities received for dematerialisation were processed, confirmed or rejected, and mutilated within prescribed timelines. This is a standard quarterly administrative filing with no financial impact.
- Compliance certificate filed for the quarter ended September 30, 2026
- Confirmation issued by Registrar MUFG Intime India Private Limited dated October 03, 2026
- Filing made under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Privi Speciality Chemicals Limited has issued a notice convening an equity shareholders' meeting on October 27, 2026, as directed by the NCLT Mumbai Bench. The meeting is to consider and approve the Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company. NCLT had earlier dispensed with meetings of creditors and transferor company members via its order dated September 7, 2026. The Appointed Date for the merger is fixed as October 1, 2025.
- Meeting of equity shareholders scheduled for October 27, 2026, at 12:30 p.m. via OAVM
- Amalgamation covers two transferor entities: Privi Fine Sciences Pvt Ltd and Privi Biotechnologies Pvt Ltd
- NCLT Mumbai Bench order pronounced on September 7, 2026, dispensing creditor meetings
- Appointed date for the proposed Scheme of Amalgamation is October 1, 2025
- BSE and NSE issued No Objection Letters on May 6, 2026, and May 5, 2026, respectively
Privi Speciality Chemicals Limited has issued a notice convening a meeting of equity shareholders on October 27, 2026, pursuant to NCLT Mumbai orders dated September 7, 2026. The meeting is called to approve the proposed Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company. Remote e-voting runs from October 22, 2026, to October 26, 2026, with an eligibility cut-off date of October 20, 2026. This formalizes the group's corporate restructuring process to integrate fine sciences and biotech operations.
- Shareholder meeting scheduled for October 27, 2026, at 12:30 p.m. IST via VC/OAVM pursuant to NCLT order dated September 7, 2026
- Scheme involves amalgamation of Privi Fine Sciences Pvt Ltd and Privi Biotechnologies Pvt Ltd into Privi Speciality Chemicals Ltd
- Remote e-voting window open from October 22, 2026 (9:00 AM) to October 26, 2026 (5:00 PM)
- Cut-off date set for October 20, 2026, to determine eligible voting shareholders
Privi Speciality Chemicals Limited announced that company officials will attend an investor conference organized by Anand Rathi Institutional Equities in Mumbai on September 22, 2026. The interactions will involve 1x1 and group meetings starting at 09:00 AM onwards. Management confirmed that discussions will be based strictly on publicly available information with no unpublished price-sensitive information (UPSI) disclosed.
- Investor conference scheduled for September 22, 2026, starting at 09:00 am onwards
- Meeting format includes 1x1 and group interactions
- Conference organized by Anand Rathi Institutional Equities in Mumbai
- No unpublished price sensitive information (UPSI) to be discussed
Privi Speciality Chemicals has scheduled an investor conference in Mumbai for August 18, 2026, organized by Motilal Oswal (MOSL). The interaction will include 1x1 and group meetings starting from 09:00 am onwards. The company recently reported a strong FY26 with revenue of ₹2,564 Cr and an operating margin of 25.2%. Discussions are expected to center on the company's '5K, 1K' vision (targeting ₹5,000 Cr revenue) and the ramp-up of the PRIGIV JV.
- Investor meeting scheduled for August 18, 2026, in Mumbai starting at 09:00 am.
- Interaction organized by Motilal Oswal (MOSL) involving 1x1 and group formats.
- Company maintains a '5K, 1K' vision targeting ₹5,000 Cr revenue and ₹1,000 Cr EBITDA.
- Current TTM revenue stands at ₹2,564 Cr with a PAT of ₹316 Cr.
- Capacity expansion to 54,000 MTPA is planned for completion by January 2026.
Privi Speciality Chemicals has filed the Scrutinizer's Report for its 41st Annual General Meeting (AGM) held on August 07, 2026. This is a procedural filing confirming that the voting process for the business transacted at the meeting has been completed in compliance with the Companies Act, 2013. While the specific resolutions are not detailed in the cover letter, the filing marks the formal conclusion of the annual shareholder meeting. The company continues to focus on its '5K, 1K' vision, targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA over the next 3-4 years.
- 41st Annual General Meeting successfully conducted on August 07, 2026
- Scrutinizer's Report on voting results submitted to exchanges on August 10, 2026
- Company maintains a TTM revenue of Rs 2,564 Cr with an OPM of 25.2%
- Current installed capacity stands at 48,000 MTPA with expansion to 54,000 MTPA expected by Jan 2026
Privi Speciality Chemicals has submitted the Scrutinizer's report for its 41st Annual General Meeting (AGM) held on August 07, 2026. The filing is a procedural requirement under Section 108 of the Companies Act, 2013, detailing the voting results for the business transacted. The company currently reports a TTM revenue of Rs 2,564 Cr and an operating profit margin of 25.2%. This announcement confirms the completion of the formal shareholder voting process for the period.
- 41st Annual General Meeting was held on August 07, 2026
- Scrutinizer's report submitted to exchanges on August 10, 2026
- Company maintains a TTM revenue of Rs 2,564 Cr and PAT of Rs 316 Cr
- Current market capitalization stands at Rs 13,542 Cr
Privi Speciality Chemicals Limited conducted its 41st Annual General Meeting (AGM) on August 07, 2026, via video conferencing with 61 members in attendance. Key resolutions presented to shareholders included the adoption of FY26 financial statements and the declaration of a ₹10.00 per share final dividend. The meeting also sought approval for the re-appointment of Mr. Mahesh Purshottam Babani as Director and Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a three-year term. No adverse remarks or qualifications were reported by the statutory or secretarial auditors for the financial year ended March 31, 2026.
- Proposed a final dividend of ₹10.00 per equity share (1000% of face value) for FY26.
- Proposed re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years starting August 13, 2026.
- The meeting was attended by 61 members and concluded within 58 minutes.
- Statutory and Secretarial Auditor reports for FY26 contained no qualifications or adverse remarks.
- Voting results to be disclosed within 2 working days from the conclusion of the AGM.
Privi Speciality Chemicals reported a strong start to FY27 with total income rising 20.01% YoY to Rs 681.42 Cr. The company maintained resilient EBITDA margins at 24.58%, supported by volume growth and price increases. A key milestone is the imminent commercialization of Phase-1 capacity expansion, increasing total capacity from 48,000 to 54,000 MTPA. Additionally, the PRIGIV JV is scaling up with a planned Rs 50 Cr equity infusion to support 42 exclusive products for Givaudan.
- Total consolidated income grew 20.01% YoY to Rs 681.42 Cr in Q1 FY27.
- Phase-1 capacity expansion to 54,000 MTPA (up from 48,000 MTPA) is expected to be commercialized shortly.
- EBITDA margins sustained at 24.58%, marking nine consecutive quarters of approximately 25% margins.
- Profit After Tax (PAT) rose to Rs 83.2 Cr, a significant increase from Rs 61.46 Cr in Q1 FY26.
- PRIGIV JV to receive Rs 50 Cr additional equity infusion for its next phase of expansion.
Privi Speciality Chemicals Limited has published the audio recording of its analyst call held on July 31, 2026, regarding the Q1 FY27 financial results. The call, which lasted 53 minutes, followed the Board's approval of the un-audited results on July 30, 2026. This filing is a standard procedural requirement to ensure transparency for all shareholders. Investors can use the recording to gauge management's progress toward their '5K, 1K' vision (Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA) and the status of the PRIGIV JV with Givaudan.
- Analyst call held on July 31, 2026, for a duration of 53 minutes (03:30 p.m. to 04:23 p.m.)
- Board of Directors approved the Q1 FY27 un-audited results on July 30, 2026
- Company maintains a long-term '5K, 1K' vision targeting Rs 5,000 Cr revenue
- Current installed capacity remains at 48,000 MTPA with expansion to 54,000 MTPA planned by January 2026
- TTM revenue stands at Rs 2,564 Cr with an operating profit margin of 25.2%
Privi Speciality Chemicals reported a strong start to FY27, with Q1 total income rising 20.01% YoY to Rs 681.42 Cr. Net Profit (PAT) surged 35.97% YoY to Rs 84.21 Cr, driven by broad-based demand and operational efficiencies. Despite a one-off fire incident at a warehouse costing Rs 2.78 Cr (impacting margins by 42 bps), EBITDA margins remained robust at 24.58%. The company is aggressively pursuing its '5K, 1K' vision, targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA by FY29-30.
- Total income grew 20.01% YoY to Rs 681.42 Cr in Q1 FY27.
- Net Profit increased by 35.97% YoY to Rs 84.21 Cr.
- EBITDA margin stood at 24.58%, showing resilience despite a Rs 2.78 Cr fire loss.
- Net Debt to EBITDA ratio significantly improved to 1.29x from 2.57x in FY24.
- ROCE improved by 299 bps YoY to 21.70% in Q1 FY27.
Privi Speciality Chemicals has formally filed its Scheme of Amalgamation with the NCLT Mumbai Bench as of June 25, 2026, to merge two subsidiaries into the parent entity. The Board also approved the Q1 FY27 financial results and reiterated a final dividend recommendation of ₹10 per share for FY26. The total dividend payout of ₹39.06 Cr represents approximately 12.3% of the company's TTM PAT of ₹316 Cr. This move follows the receipt of observation letters from NSE and BSE in early May 2026.
- Filed Scheme of Amalgamation with NCLT Mumbai on June 25, 2026, for merging two entities.
- Recommended a final dividend of ₹10 per equity share for the financial year ended March 31, 2026.
- Total dividend payout aggregates to ₹3,906.27 lakhs (₹39.06 Cr).
- Received regulatory observation letters from NSE and BSE on May 5 and May 6, 2026, respectively.
- The merger involves Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited.
Privi Speciality Chemicals approved its unaudited Q1 FY27 results for the period ended June 30, 2026. The company has formally filed its Scheme of Amalgamation for Privi Fine Sciences and Privi Biotechnologies with the NCLT Mumbai Bench as of June 25, 2026. A final dividend of Rs 10 per share for FY26, totaling Rs 39.06 Cr, is pending shareholder approval. The company continues to pursue its '5K, 1K' vision, targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA over the next 3-4 years.
- Final dividend of Rs 10 per equity share recommended for FY26, aggregating to Rs 3,906.27 lakhs
- Scheme of Amalgamation filed with NCLT Mumbai Bench on June 25, 2026
- Observation letters for the merger received from NSE and BSE on May 05 and May 06, 2026, respectively
- Company targeting capacity expansion to 54,000 MTPA by January 2026
- PRIGIV JV ramping up to manufacture 42 exclusive products for Givaudan SA
Privi Speciality Chemicals has scheduled its earnings conference call for Friday, July 31, 2026, at 3:30 PM IST to discuss Q1 FY27 results. The management team, including the Chairman & MD and CFO, will address operational and financial performance for the quarter ended June 30, 2026. This follows a strong TTM performance with revenue of ₹2,564 Cr and an OPM of 25.2%. Investors will likely seek updates on the '5K, 1K' vision and the progress of the PRIGIV JV.
- Earnings conference call scheduled for July 31, 2026, at 15:30 hrs IST
- Focus on operational and financial performance for the quarter ended June 30, 2026
- Transcript of the call to be available on the company website within 5 working days
- Management participation includes the Chairman & MD, President, and CFO
- Company currently maintains a TTM revenue of ₹2,564 Cr and a market cap of ₹13,655 Cr
Privi Speciality Chemicals has scheduled its 41st Annual General Meeting (AGM) for August 07, 2026, to be held via video conferencing. The company has dispatched notices to shareholders holding physical shares, providing the specific web-link to access the Integrated Annual Report for FY 2025-26. This filing is a procedural requirement under SEBI Regulation 36(1)(b) to ensure all shareholders, including those without registered emails, have access to financial disclosures. The report will contain detailed progress on the company's '5K, 1K' vision (Rs 5,000 Cr revenue target).
- 41st Annual General Meeting (AGM) to be held on August 07, 2026, at 04:00 p.m. IST
- Annual Report for FY 2025-26 made available via a dedicated web-link dispatched on July 13, 2026
- Cut-off date for identifying shareholders for physical dispatch was July 03, 2026
- Company is pursuing a '5K, 1K' vision targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA
- Capacity expansion to 54,000 MTPA is planned for completion by January 2026
Financial Performance
Revenue Growth by Segment
Consolidated total income grew 19.3% in FY25 to INR 2,121.84 Cr. In H1 FY26, revenue grew 24% YoY to INR 1,246.08 Cr, driven by a 20% QoQ growth between Q2 and Q1 FY26 from flagship and newly introduced products.
Geographic Revenue Split
Exports account for over 65% of total revenue, reaching customers in more than 30 countries. Domestic sales contribute the remaining balance of less than 35%.
Profitability Margins
Profit After Tax (PAT) for FY25 grew 92.6% to INR 184.61 Cr from INR 95.84 Cr. H1 FY26 PAT grew 94% YoY to INR 147.76 Cr, reflecting improved management of raw material costs and higher volumes.
EBITDA Margin
EBITDA margin for FY25 was approximately 22.3%. H1 FY26 EBITDA margin improved to 25.94%, with Q2 FY26 reaching a record high of 26.83% (up 59% YoY in absolute terms to INR 182.14 Cr) due to byproduct value addition and de-bottlenecking.
Capital Expenditure
Total capital expenditure of INR 178 Cr is allocated for the PRIGIV joint venture and a greenfield facility in Mahad, Maharashtra. Phase-1 expansion was completed ahead of schedule.
Credit Rating & Borrowing
CRISIL Ratings monitors gearing with a downward sensitivity factor if it sustains above 1.15 times. Upward rating factors include strengthening the business profile and maintaining a working capital cycle below 150 days.
Operational Drivers
Raw Materials
Specific raw materials include pinene-based, citral-based, and phenol-based chemicals, as well as various crude oil derivatives.
Import Sources
Over 55% of raw materials are imported from global markets to ensure supply continuity and cost-effectiveness.
Capacity Expansion
Current installed capacity is 48,000 MTPA. Planned expansion will increase available capacity to 54,000 MTPA by January 2026. Long-term vision targets a '5K, 1K' goal over the next 3-4 years.
Raw Material Costs
Raw material costs are stabilized through long-term contracts and strategic hedging. Management of these costs was a primary driver for the 92.6% increase in PAT during FY25.
Manufacturing Efficiency
Capacity utilization reached 92% in H1 FY26. Efficiency is driven by continuous innovation and value addition through byproducts.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth will be achieved through the '5K, 1K' vision (targeting INR 5,000 Cr revenue and INR 1,000 Cr EBITDA), the PRIGIV JV which will manufacture 42 exclusive products for Givaudan SA, and increasing capacity to 54,000 MTPA by Jan 2026.
Products & Services
Aroma and fragrance chemicals (over 75 specialized products) used as ingredients for manufacturing fragrances for the global FMCG and flavor industries.
Brand Portfolio
Privi, PRIGIV (Joint Venture).
New Products/Services
The PRIGIV JV is ramping up to manufacture 42 high-end products exclusively for Givaudan SA, which is expected to provide meaningful contributions in the coming years.
Market Expansion
Expansion is focused on high-end product lines for global leaders and increasing reach beyond the current 30+ countries.
Market Share & Ranking
India's leading manufacturer, supplier, and exporter of aroma and fragrance chemicals.
Strategic Alliances
Strategic partnership and 51% Joint Venture (PRIGIV) with Givaudan SA for exclusive product manufacturing.
External Factors
Industry Trends
The aroma chemicals market is shifting toward sustainable and advanced solutions. Privi is positioned in the top 5% of global manufacturers for sustainability with an EcoVadis Gold Certification.
Competitive Landscape
Key dynamics involve competing with Chinese manufacturers and global aroma chemical firms by leading with purpose and responsible growth.
Competitive Moat
Durable advantages include the strategic JV with Givaudan SA, process intensification capabilities, and a 'Gold' sustainability rating which acts as a high entry barrier for competitors.
Macro Economic Sensitivity
Highly sensitive to crude oil price volatility and USD/INR exchange rate fluctuations due to the high volume of imports (55%) and exports (65%).
Consumer Behavior
Increasing consumer and regulatory demand for sustainable and transparently sourced fragrance ingredients.
Geopolitical Risks
Competition from China is a noted threat, which the company mitigates through its sustainability differentiator and long-standing global FMCG relationships.
Regulatory & Governance
Industry Regulations
Operations comply with Indian Accounting Standards (Ind AS) and relevant provisions of the Companies Act, 2013. Adheres to global manufacturing standards for aroma chemicals.
Environmental Compliance
Compliant with ISO 14001:2015 and ISO 45001:2018. Holds EcoVadis Gold Certification for sustainability performance.
Taxation Policy Impact
Received INR 9 Cr in state incentives during H1 FY26 from Gujarat and Maharashtra. The company is pursuing 'Ultra Mega' status to extend incentive eligibility to a 20-year period.
Legal Contingencies
Statutory auditors reported no instances of fraud by officers or employees during the year under Section 143(12) of the Act.
Risk Analysis
Key Uncertainties
Foreign exchange rate risk (USD/INR) and raw material price volatility (crude derivatives) are the primary uncertainties impacting financial performance.
Geographic Concentration Risk
Over 65% of revenue is concentrated in export markets across 30+ countries.
Third Party Dependencies
Strategic dependency on Givaudan SA for the PRIGIV JV, which is of 'utmost strategic importance' to the company's high-end product growth.
Technology Obsolescence Risk
Mitigated by a dedicated R&D team and focus on process intensification and de-bottlenecking to maintain manufacturing leadership.
Credit & Counterparty Risk
Financial risk profile is considered above-average due to a comfortable capital structure and adequate debt protection metrics.
